Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy.
Edward J Bastyr, Karen L Price, Vera Bril...
https://pubmed.ncbi.nlm.nih.gov/16199253/Actively Recruiting
Led by Thammasat University · Updated on 2026-07-21
66
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the effects of benfotiamine compared to vitamin B1-6-12 in adults with diabetic peripheral neuropathy. This condition causes sensory neuropathy symptoms, numbness, and pain, and the study aims to find out if benfotiamine reduces these symptoms more effectively than vitamin B1-6-12. The trial is a phase 4, randomized, double-blind study designed to compare these treatments over 12 weeks. Participants will be randomly assigned to one of two groups one receiving benfotiamine 150 mg twice daily, and the other receiving a combined vitamin B1 100 mg, B6 5 mg, and B12 65 mcg pill twice daily. Both treatments are given orally for three months and are made to look identical to keep the study blinded. Before enrollment, participants will be screened for vitamin B12 deficiency, and those with low levels will not be eligible. During the study, participants will have two in-person clinic visits at the start and end of the 12-week treatment period, along with two telephone follow-ups. They will continue their usual medications as long as no new neuropathic pain treatments are started and existing doses remain stable. Researchers will assess changes in neuropathy symptoms, numbness, and pain over the course of treatment using standardized symptom scores and patient impressions of change.
CONDITIONS
Benfotiamine Versus Vitamin B1-6-12 for Diabetic Peripheral Neuropathy
S
Supitcha Lamlertpanya
A
Arom Jedsadayanmata
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Thammasat University
Lead Sponsor
Wörwag Pharma GmbH & Co. KG
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 weeks
Participants take either benfotiamine or vitamin B1-6-12 orally twice daily for 12 weeks. They continue their usual medications without changes to neuropathic pain treatments during this time.
2 in-person clinic visits and 2 telephone follow-ups
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Edward J Bastyr, Karen L Price, Vera Bril...
https://pubmed.ncbi.nlm.nih.gov/16199253/Thanompong Sathienluckana, Sirinoot Palapinyo, Kitiyot Yotsombut...
https://pubmed.ncbi.nlm.nih.gov/38333576/Heather Gerould, Rikki Mangrum, Rebecca L Robinson...
https://pubmed.ncbi.nlm.nih.gov/41257214/Dan Ziegler, Solomon Tesfaye, Vincenza Spallone...
https://pubmed.ncbi.nlm.nih.gov/34547367/H Stracke, W Gaus, U Achenbach...
https://pubmed.ncbi.nlm.nih.gov/18473286/Iva Bozic, Irena Lavrnja
https://pubmed.ncbi.nlm.nih.gov/38034619/Pitchai Balakumar, Ankur Rohilla, Pawan Krishan...
https://pubmed.ncbi.nlm.nih.gov/20188835/E Haupt, H Ledermann, W Köpcke
https://pubmed.ncbi.nlm.nih.gov/15726875/David A Fraser, Lien M Diep, Inger Anette Hovden...
https://pubmed.ncbi.nlm.nih.gov/22446172/Thammasat University
Lead Sponsor
Wörwag Pharma GmbH & Co. KG
Collaborating Sponsor